Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib and Sonrotoclax in Relapsed CLL/SLL (ZeuS-2 Trial)
NCT07812246Phase 2Not yet recruiting
- Sponsor
- City of Hope
- Start
- Aug 2027
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax, zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by City of Hope. Planned start Aug 2027; status: not yet recruiting.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07812246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812246.